Edition:
India

Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

109.41USD
15 Dec 2017
Change (% chg)

$1.17 (+1.08%)
Prev Close
$108.24
Open
$109.28
Day's High
$109.64
Day's Low
$107.69
Volume
6,516,647
Avg. Vol
2,205,991
52-wk High
$147.13
52-wk Low
$94.56

Select another date:

Thu, Dec 7 2017

BRIEF-Celgene Reports Long-Term Efficacy Data From Phase III Geparsepto Study

* LONG-TERM EFFICACY DATA FROM THE PHASE III GEPARSEPTO STUDY IN HIGH RISK EARLY BREAST CANCER PATIENTS TREATED WITH ABRAXANE VS. SOLVENT-BASED PACLITAXEL TO BE REPORTED

BRIEF-Celgene Corp and bluebird bio announce bb2121 anti-BCMA CAR-T cell therapy has been granted Breakthrough Therapy designation from FDA

* Celgene Corp and bluebird bio announce bb2121 anti-BCMA CAR-T cell therapy has been granted Breakthrough Therapy designation from FDA and prime eligibility from EMA for relapsed and refractory multiple myeloma

BRIEF-Temasek Holdings (Private) Ltd ups share stake in Mastercard, Visa and Monsanto

* Temasek Holdings (Private) Ltd ups share stake in Mastercard to 923,068 class a shares from 267,006 class a shares

BRIEF-Celgene prices $3 billion of senior unsecured notes

* Celgene Corp - ‍announced pricing of three series of senior unsecured notes for aggregate principal amount of $3,000 million​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Celgene announces offering of senior unsecured notes

* Celgene-To use proceeds for repayment of $1 billion outstanding 2.125% senior notes & $400 million outstanding 2.300% senior notes, each maturing Aug 2018​ Source text for Eikon: Further company coverage:

BRIEF-Lannett and Celgene enter into settlement and license agreement related to Thalomid

* Lannett and Celgene enter into settlement and license agreement related to Thalomid

BRIEF-Celgene Corp updates on court order at request of Canadian Competition Bureau - SEC filing

* Celgene Corp says ‍​in Aug, co received an order issued by the Federal Court in Ottawa, Ontario, Canada at request of Canadian Competition Bureau

Celgene cuts 2020 outlook, Otezla sales disappoint; shares plunge

Celgene Corp on Thursday reported third-quarter sales of its key psoriasis drug Otezla that badly missed expectations and significantly scaled down its 2020 targets for product sales and earnings, sending its shares tumbling 18 percent.

BRIEF-Celgene initiating share repurchase plan

* Celgene CFO says initiating share repurchase plan beginning immediately Source text for Eikon: Further company coverage: (Reporting By Bill Berkrot)

BRIEF-Celgene reports Q3 earnings per share of $1.21

* Celgene reports third quarter 2017 operating and financial results

Select another date: